Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
复制标题
使用低分子量药物 (LMWD) 靶向治疗慢性阻塞性肺疾病 (COPD)。
DOI：
10.1021/acs.jmedchem.8b01520
复制
发表时间：
2019
影响因子：
7.3
通讯作者：
Zhao Xin
中科院分区：
文献类型：
--
作者：
Ti Huihui;Zhou Yang;Liang Xue;Li Runfeng;Ding Ke;Zhao Xin
慢性阻塞性肺疾病（COPD）是一种非常常见且经常致命的气道疾病。目前COPD的治疗主要依赖于长效支气管扩张剂，其不能靶向COPD慢性炎症的致病机制。迫切需要针对COPD炎症过程的新药物疗法。基于对COPD发病机制的进一步了解，已经确定了几个抗炎靶点，这为这种致命的呼吸道疾病的靶向治疗带来了新的希望。本文综述了近年来用于COPD治疗的生物活性低分子药物（LMWD）的研究进展，除一线药物支气管扩张剂外，还重点介绍了低分子抗炎药，包括炎症介质调节剂、炎性体抑制剂、蛋白酶抑制剂、抗氧化剂、PDE 4抑制剂、激酶抑制剂等。我们还提供了使用LMWD（特别是小分子药物）靶向COPD治疗的新见解。
Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the pathogenic mechanisms of chronic inflammation in COPD. New pharmaceutical therapies for the inflammatory processes of COPD are urgently needed. Several anti-inflammatory targets have been identified based on increased understanding of the pathogenesis of COPD, which raises new hopes for targeted treatment of this fatal respiratory disease. In this review, we discuss the recent advances in bioactive low-molecular-weight drugs (LMWDs) for the treatment of COPD and, in addition to the first-line drug bronchodilators, focus particularly on low-molecular-weight anti-inflammatory agents, including modulators of inflammatory mediators, inflammasome inhibitors, protease inhibitors, antioxidants, PDE4 inhibitors, kinase inhibitors, and other agents. We also provide new insights into targeted COPD treatments using LMWDs, particularly small-molecule agents.